Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.
The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The deal is the first for Hong Kong-based Prenetics and marks its foray into the consumer genomics space.
Roche noted that Flatiron partners with more than 265 community cancer clinics, six major academic research centers, and 14 therapeutic oncology companies.
Element Genomics' technology will increase UCB's pipeline, focusing on target discovery and interpretation in disease relevant systems.
Thompson Street will acquire YX Genomics Holding, the holding company of Transnetyx and two other subsidiaries.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.